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ABSTRACT   
Hepatocellular carcinoma is one of the most common types of liver cancer causing death all over the world. Although 
early-stage liver cancer can sometimes be treated with partial hepatectomy, liver transplantation, ablation, and 
embolization, sorafenib treatment is the only approved systemic therapy for advanced HCC. The aim of this research is 
to develop tools and methods to understand the individuality of hepatocellular carcinoma. Microfluidic cell-culture 
platform has been developed to observe behavior of single-cells; fluorescence microscopy has been implemented to 
investigate phenotypic changes of cells. Our preliminary data proved high-level heterogeneity of hepatocellular 
carcinoma while verifying limited growth of liver cancer cell lines on the silicon wafer.  
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1. INTRODUCTION  
Primary liver cancer is one of the most lethal tumor types in the world with approximately one million cases per year [1]. 
Hepatocellular carcinoma (HCC), as a histological type of primary liver cancer, has poor systemic molecular targeted 
therapies, which has been admitted widely due to enormous intertumor and intratumor heterogeneity in HCC [1,3]. 
Although, partial hepatectomy, liver transplantation, ablation and embolization, sorafenib treatment (Nexavar, Bayer 
HealthCare Pharmaceuticals) can sometimes cure early-stage liver cancer [4,5], still our understanding of its 
heterogeneity and treatment of liver cancer is at its crawling stage. There are several mechanisms that drive tumor 
heterogeneity such as etiological and environmental factors, patient ethnicity, cancer stem cells, and diversity in genetics 
and epigenetics [6]. 
Various methods ranging from genomic profiling to functional analyses have been implemented to understand the 
heterogeneity of liver cancer [1]. However, development of novel tools and methods to better understand cellular 
individuality and quantitatively characterize heterogeneity of HCC is still crucial. Hence, single-cell assays might 
compensate the limitations of bulk assays such as averaging the entire population and masking rare phenotypes [7]. 
Moreover, these assays might provide direct and quantitative readouts instead of averaging measurements. Microfluidic 
technologies in combination with advanced imaging systems present promising tools in this area. These tools are eligible 
to culture cells using well-controlled growth conditions and obtaining real-time measurements [8-9]. Besides, these 
modern methods reduce the assay time, sample consumption and waste production, while improving the throughput and 
precision.  
In this study, we developed a microfluidic platform, which allows growth and real-time observation of HepG2 liver 
cancer cells using inverted fluorescent microscopy. Our preliminary results were consistent with [10], liver cancer cells 
exhibited limited growth on silicon wafer.    
 
 
2. METARIALS AND METHODS 
2.1 Reagents and cell culture in batch 
HepG2 liver cancer cells, provided by Gebze Technical University Molecular Biology and Genetics department, were 
used to demonstrate the utility of the microfluidic cell culture platform. These cells were cultured in DMEM 
supplemented (PAN-Biotech) with 10% FBS (Sigma-Aldrich) both in 75cm2-flasks (Corning® T-75 flasks) and in the 
 
 
 
 
 
 
microfluidic chips inside the incubator (NUVE EC160) where 37 ˚C, 5% CO2 and humidity were provided. Trypsin-
EDTA solution (Sigma-Aldrich) was used to detach the cells from the flask and to load those cells into the microfluidic 
chips. 
2.2 Microfluidic device fabrication 
The designs were patterned on a thin film chromium deposited-photo mask (Cr-blank) using Vistec/EBPG5000plusES 
Electron Beam Lithography system. SU-8 3050 (SU-8® 3050, MicroChem) was spin coated on a 4-inches silicon wafer 
to obtain the structures with 50-µm heights. Next, the photoresist-coated wafers were soft baked at 65 ˚C for 1 minute 
and at 95 ˚C for 5 minutes. Afterwards, they were exposed to UV light (160 mJ/cm2) using the e-beam written masks by 
Midas/MDA-60MS mask aligner. Upon two consecutive post baking process at 65 ˚C for 1 minute and at 95 ˚C for 5 
minutes, they were developed for 5 minutes using MicroChem’s SU-8 developer. Later, they were rinsed with 
isopropanol.   
The wafers were used as molds for the elastomeric polymer, polydimethysiloxane (PDMS, Sylgard® 184, Dow Corning, 
Midland, MI). PDMS base and curing reagents were mixed at 10:1 ratio. Upon bubble removal through vacuuming for 
30 minutes, the mixture was baked at 75 ˚C for 60 minutes. Then, the PDMS devices were cut and the inlet and outlet 
ports were cut. Finally, the PDMS chips were bonded to a glass slide using Corona system (BD20-AC, Electro-Technic 
Products Inc.). 
2.3 Cell culture in microfluidic device 
Before cell loading into the microfluidic devices cell culture platform, metal couplers and tips couplers were autoclaved 
(Hirmaya (HMC) HV-85L) and tips were attached to medium inlet and outlet ports. Prior to usage, the medium was 
warmed at 37-˚C water bath. HepG2 cells were centrifuged at 1800rpm for 10 minutes in 15ml falcons. Next, the 
supernatant was removed, and the pellet was completed to 1ml with fresh DMEM with %10 FBS. Then, the cells were 
counted with hemocytometer and loaded into the device by a pipetman, connected to a blunt needle with a modified tip, 
with approximately 100000 cells/ml. The chambers were filled with cells through the cell trapping mechanism in single 
cell resolution. The microfluidic platform was placed into an autoclaved glass beaker with tissues wetted with phosphate 
buffered saline (PBS, Sigma-Aldrich) to prevent medium evaporation from the PDMS device. After microscopy 
inspection (Carl Zeiss, Primovert Model Trinocular Inverted Microscope) of the cells in the microfluidic cell culture 
platform, the device was transferred into the incubator overnight. 
2.4 Microscopy and image analysis 
The images of the individual chambers within the devices were captured using 10x objective using a Carl Zeiss, Axio 
Observer Z1 motorized stage equipped with the AxioCam Mrc5 camera. The cell images were obtained using 12.5 ms 
exposure under transparent light. Upon imaging, we manually counted the number of cells with and without pseupodium.  
 
3. RESULTS 
We developed our PDMS-glass device using soft lithography [11]. Figure 1 shows the design and dimensions of the 
device. 
 
Figure 1. Design of the microfluidic chip with dimensions (a) and an image of the operating device (b).  
 
 
 
 
 
 
 
Growth of the hepatocellular carcinoma cell line is observed both at population-level using batch culture and at single-
cell level using microfluidic-microscopy system above.  Figure 2 shows growth of the hepatocellular cells over night at 
batch culture and microfluidic device. 
 
Figure 2. Morphology of HepG2 cells in tissue culture petri dish (a) and PDMS-Silicon microfluidic device (b) overnight at 
37˚C. 
Both morphology images show heterogeneity of the cells; some cells have developed cellular pseupodium while some of 
them have stayed circular, and these cells either developed some pseupodium in later stage of their inoculation or they 
have never generated.  
Figure 3 shows the number of single-cells those developed pseupodium after overnight growth both in batch culture and 
microfluidic device.  
 
 
Figure 3. Single-cell analysis of liver cancer cells with and without pseupodium. 
 
4. DISCUSSION AND CONCLUSION 
Our preliminary result shows the morphological difference of overnight grown liver cancer cell lines in the tissue-culture 
petri dish and microfluidic device. The HepG2 cell line did not develop pseupodium when they were cultured in the 
PDMS-glass microfluidic device. Our preliminary results support the Xiaohui et al. [1]. When the cells did not grow 
pseupodium, they could not attach the surface of the glass and grow. They survived only a few days with the spherical 
morphology and they created cellular clusters. When we stained these clusters with DAPI and propodium iodide, we 
observed that most of the cells were dead. Therefore, when microfluidic technologies are developed, the limitations of 
 
 
 
 
 
 
the system should be carefully investigated, otherwise it might easily lead us to speculate about developing on-chip liver 
cancer spheroids using PDMS-glass microfluidic chip.  
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